Kevin Murray is a Cardiology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
804 Johns Hopkins Dr
Greenville, NC 278347222
Telephone
252-757-1000Provider last certified this registry record 12 Jan 2022.
Clinical trials
- Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma
Sponsor: Children's Cancer and Leukaemia Group
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20257 payments
- Bayer Healthcare Pharmaceuticals Inc.Program year20255 payments
- Novartis Pharmaceuticals CorporationProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
85.1%Beta blocker24.1%Metoprolol Succinate44%Carvedilol18%Nebivolol Hcl18%Metoprolol Tartrate11%Atenolol4%Sotalol2%Bisoprolol Fumarate2%Labetalol Hcl1%Part D<11 patientsCalcium channel blocker9%Amlodipine Besylate68%Diltiazem 24hr Er (Cd)20%Diltiazem Hcl5%Verapamil Er3%Verapamil Er Pm2%Diltiazem 24hr Er2%Part D<11 patients+ 14 more classes in this area
Blood & clotting
13.2%Factor Xa inhibitor9.7%Xarelto53%Eliquis47%Part D≥57 patientsP2Y12 inhibitor3.4%Clopidogrel55%Brilinta46%Part D≥21 patientsMetabolism & gastrointestinal
1.5%Potassium supplement0.9%Potassium Chloride100%Part D≥12 patientsSGLT2 inhibitor0.7%Farxiga100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”